Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LIPA | P38571 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12114914 | 0.85 | SMN1; SMN2 (0.42) | POLBLMNASMN1; SMN2TSHRRECQL | |
| SCHEMBL1318565 | 0.78 | MEN1 (0.64) | SMN1; SMN2L3MBTL1KMT2AMEN1NPSR1 | |
| SCHEMBL31167957 | 0.77 | HSD11B1 (0.46) | POLBL3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL17093002 | 0.76 | SMN1; SMN2 (0.46) | POLBLMNASMN1; SMN2TSHRRECQL | |
| SCHEMBL19959138 | 0.75 | SMN1; SMN2 (0.45) | POLBLMNASMN1; SMN2TSHRRECQL | |
| SCHEMBL1319020 | 0.74 | L3MBTL1 (0.34) | POLBLMNASMN1; SMN2TSHRRECQL | |
| SCHEMBL18353141 | 0.74 | SMN1; SMN2 (0.53) | POLBLMNASMN1; SMN2TSHRRECQL | |
| SCHEMBL22978758 | 0.74 | ALDH1A1 (0.47) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL28970514 | 0.74 | ALDH1A1 (0.39) | LMNASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL1318178 | 0.73 | MEN1 (0.66) | SMN1; SMN2KMT2AMEN1NPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380878-B1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| EP-2380878-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | BMP2, BMP4, BMP1 | POLB 3587/4885LMNA 3066/4885SMN1; SMN2 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.